Articles related to PRECISION MEDICINE

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

Tempus AI, leveraging one of the world’s largest clinical and molecular oncology data libraries, files for an IPO, aiming to raise substantial funds to support its mission of advancing AI-powered precision medicine.

Manifest Technologies is spearheading the use of AI in developing targeted treatments for CNS disorders, aiming to refine patient selection in clinical trials and enhance therapeutic outcomes.

As physicians, understanding the new biomarker legislation is crucial—it not only shapes insurance coverage but also influences clinical decision-making and patient access to precision medicine, potentially leading to more cost-effective and targeted care.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.

This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.